NCT02170727 - A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

June 26, 2014

Primary Completion Date

June 12, 2015

Study Completion Date

September 9, 2015

Conditions

Hepatitis C Virus

Interventions

DRUG

DCV/ASV/BMS-791325

Trial Locations (20)

100

Local Institution, Taipei

112

Local Institution, Taipei

333

Local Institution, Taoyuan District

704

Local Institution, Tainan City

807

Local Institution, Kaohsiung City

833

Local Institution, Kaohsiung City

40447

Local Institution, Taichung

40705

Local Institution, Taichung

109240

Local Institution, Moscow

420140

Local Institution, Kazan'

602-739

Local Institution, Busan

614-735

Local Institution, Busan

463-707

Local Institution, Gyeonggi-do

480-717

Local Institution, Gyeonggi-do

626-770

Local Institution, Gyeongsangnam-do

405-760

Local Institution, Inchoen

120-752

Local Institution, Seoul

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

156-755

Local Institution, Seoul